scholarly journals Concentrated lyophilized plasma used for reconstitution of whole blood leads to higher coagulation factor activity but unchanged thrombin potential compared with fresh-frozen plasma

Transfusion ◽  
2017 ◽  
Vol 57 (7) ◽  
pp. 1763-1771 ◽  
Author(s):  
Giacomo E. Iapichino ◽  
Martin Ponschab ◽  
Janne Cadamuro ◽  
Susanne Süssner ◽  
Christian Gabriel ◽  
...  
Keyword(s):  
Whole Blood ◽  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Factor Activity ◽  
Fresh Frozen ◽  
Frozen Plasma

Coagulation factor activity in units of leukoreduced and nonleukoreduced canine fresh-frozen plasma

2019 ◽  
Vol 80 (9) ◽  
pp. 846-851
Author(s):  
Michelle L. Foote ◽  
Marjory B. Brooks ◽  
Todd M. Archer ◽  
Robert W. Wills ◽  
Andrew J. Mackin ◽  
...  
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Factor Activity ◽  
Fresh Frozen ◽  
Frozen Plasma

Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage

Transfusion ◽  
2009 ◽  
Vol 49 (8) ◽  
pp. 1584-1591 ◽  
Author(s):  
Erik Scott ◽  
Kathleen Puca ◽  
Jennifer Heraly ◽  
Jerome Gottschall ◽  
Kenneth Friedman
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Factor Activity ◽  
C Storage ◽  
Fresh Frozen ◽  
Frozen Plasma

Effect of Whole Blood Storage on Factor VIII Recovery in Fresh Frozen Plasma and Cryoprecipitate

Vox Sanguinis ◽  
1996 ◽  
Vol 71 (3) ◽  
pp. 150-154 ◽  
Author(s):  
D. P. Allersma ◽  
R. M. R. Imambaks ◽  
L. J. Meerhof
Keyword(s):  
Factor Viii ◽  
Whole Blood ◽  
Fresh Frozen Plasma ◽  
Blood Storage ◽  
Fresh Frozen ◽  
Frozen Plasma

Perioperative management of coagulation

2006 ◽  
Vol 26 (S 02) ◽  
pp. S3-S14 ◽  
Author(s):  
P. Innerhofer
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Laboratory Evaluation ◽  
Blood Component ◽  
Actual Case ◽  
Fresh Frozen ◽  
Coagulation Factor Concentrates ◽  
Hemostatic Therapy ◽  
Frozen Plasma

SummaryGuidelines of official societies for diagnosis and therapy of intraoperatively occurring hypocoagulability rely mainly on data of patients receiving whole blood transfusions. They recommend -provided that laboratory evaluation shows deficiency (values >1.5 fold normal)- administration of fresh frozen plasma, cryoprecipitate and platelet concentrates (platelet count <50 000 or <100 000/μl). This article describes the pathogenesis of coagulopathy in the light of the special intraoperative setting, emphasizes recent changes of blood component preparation, transfusion triggers, effects of volume therapy and challenges standard laboratory assays as reliable guide for intraoperative hemostatic therapy. The role of thrombelastographic monitoring is discussed as well as an alternative strategy to compensate deficiencies by the use of coagulation factor concentrates instead of or in addition to transfusion of FFP, a new concept which is illustrated by the presentation of an actual case report.

scholarly journals Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma

Blood ◽  
1992 ◽  
Vol 79 (3) ◽  
pp. 826-831 ◽  
Author(s):  
B Horowitz ◽  
R Bonomo ◽  
AM Prince ◽  
SN Chin ◽  
B Brotman ◽  
...  
Keyword(s):  
Sindbis Virus ◽  
Animal Studies ◽  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Complete Inactivation ◽  
Virus Safety ◽  
Fresh Frozen ◽  
History Of ◽  
Triton X ◽  
Frozen Plasma

Abstract Fresh frozen plasma (FFP) is prepared in blood banks world-wide as a by- product of red blood cell concentrate preparation. Appropriate clinical use is for coagulation factor disorders where appropriate concentrates are unavailable and when multiple coagulation factor deficits occur such as in surgery. Viral safety depends on donor selection and screening; thus, there continues to be a small but defined risk of viral transmission comparable with that exhibited by whole blood. We have prepared a virus sterilized FFP (S/D-FFP) by treatment of FFP with 1% tri(n-butyl)phosphate (TNBP) and 1% Triton X-100 at 30 degrees C for 4 hours. Added reagents are removed by extraction with soybean oil and chromatography on insolubilized C18 resin. Treatment results in the rapid and complete inactivation of greater than or equal to 10(7.5) infectious doses (ID50) of vesicular stomatitis virus (VSV) and greater than or equal to 10(6.9) ID50 of sindbis virus (used as marker viruses), greater than or equal to 10(6.2) ID50 of human immunodeficiency virus (HIV), greater than or equal to 10(6) chimp infectious doses (CID50) of hepatitis B virus (HBV), and greater than or equal to 10(5) CID50 of hepatitis C virus (HCV). Immunization of rabbits with S/D-FFP and subsequent adsorption of elicited antibodies with untreated FFP confirmed the absence of neoimmungen formation. Coagulation factor content was comparable with that found in FFP. Based on these laboratory and animal studies, together with the extensive history of the successful use of S/D-treated coagulation factor concentrates, we conclude that replacement of FFP with S/D-FFP, prepared in a manufacturing facility, will result in improved virus safety and product uniformity with no loss of efficacy.

Study of coagulation factor activities in apheresed thawed fresh frozen plasma at 1–6°C for five days

2006 ◽  
Vol 21 (4) ◽  
pp. 224-226 ◽  
Author(s):  
Rameshwar S. Sidhu ◽  
Tuan Le ◽  
Brad Brimhall ◽  
Hannis Thompson
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Frozen Plasma

Coagulation Factor Activity in Therapeutic Plasma Prepared from Whole Blood with Pathogen Inactivation (INTERCEPT™) Treatment.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4149-4149
Author(s):  
Jean-Pierre Cazenave ◽  
Hervé Isola ◽  
Marie-Louise Wiesel ◽  
Daniel Kientz ◽  
Michel Laforêt ◽  
...  
Keyword(s):  
Whole Blood ◽  
Total Protein ◽  
Frozen Storage ◽  
Coagulation Factor ◽  
Coagulation Factors ◽  
Blood Collection ◽  
Pathogen Inactivation ◽  
Factor Activity ◽  
Illumination Time ◽  
Frozen Plasma

Abstract Background. A photochemical treatment (PCT) using amotosalen HCl (S-59) and UVA light was developed to inactivate pathogens and leukocytes in therapeutic plasma (INTERCEPT™, I-FFP) frozen within 8 hr of collection. Previous studies demonstrated a broad spectrum of pathogen inactivation (Transfusion2006;46:1168) and clinical efficacy of I-FFP for support of coagulopathies (Transfusion2005;45:1362; Blood2006; 107:3753), and plasma exchange of TTP (Transfusion 2006;46). Preparation of therapeutic plasma from whole blood would complement blood center logistics and reduce the cost of therapeutic frozen plasma provided sufficient coagulation factors were retained. Aims. We measured coagulation factors in plasma isolated from whole blood held overnight at controlled temperature (21 ± 3°C), processed with pathogen inactivation, and frozen within 18 hr of blood collection. Methods. Whole blood units, approximately 460 mL, anticoagulated with CPD (Baxter, La Chatre, France) were drawn from group A, O, B and AB donors. Units were processed after 16 hr storage, and plasma was isolated by centrifugation. Two to 3 plasma units of matched blood group were pooled (n = 30: A = 14, O = 14, B = 1, AB =1) to a final volume of 635 mL. Baseline samples for assay of coagulation factors were withdrawn. Each of 30 pools was mixed with 15 mL of 6 mM amotosalen (150 uM: final concentration) and illuminated with a 3 J/cm2 UVA treatment. Following illumination (~ 8 min) and passage through a flow compound adsorption device (~20 min) to reduce levels of residual S-59, treated plasma units (650 mL) were divided into 3 equal storage units of ≥ 200 mL. Before freezing, post-treatment samples for assay of coagulation factors were withdrawn for assay of coagulation factors. Treated plasma units were flash frozen at -80°C, and transferred to −30°C for 12-month storage. Treated units were withdrawn after 1 month to measure total protein, albumin, IgG, IgM, IgA, fibrinogen, factors II, V, VII, VIII, IX, X, XI, XII, VIII-vWF, Proteins C and S, AT III, plasminogen, alpha-2 antiplasmin, D-dimers, PT, and APTT. Results. Baseline coagulation factor levels (Mean ± SD) were in suitable therapeutic ranges. After PCT, all units had residual platelets &lt; 1×109/L, WBC &lt; 1×104/L, and RBC &lt; 1 × 109/L. After PCT and frozen storage for 1 month, total protein (59 ± 2 g/L), albumin (38 ± 1 g/L), IgG (8.9 ± 1.1g/L), IgA (1.8 ± 0.4 g/L) and IgM (0.9 ± 0.3 g/L) were unchanged from baseline. Mean values for fibrinogen (g/L), coagulation factors (IU/dL), coagulation inhibitors (IU/dL), were variably reduced from baseline, but within ranges defined as suitable for therapeutic plasma (Table). There was no evidence of plasma activation. Conclusions. Plasma prepared from whole blood after storage on cooling plates before processing with the INTERCEPT system for pathogen inactivation retained coagulation factor activity levels after frozen storage (−30°C) in conformance with French national standards for therapeutic frozen plasma (FP). Approximately 36 units (200 mL) could be prepared per hr of illumination time with this system.

EFFECT OF TRANSFUSION OF AUTOLOGOUS WHOLE BLOOD VS. AUTOLOGOUS PACKED RED CELLS AND FRESH FROZEN PLASMA ON THE IMMUNE SYSTEM OF HEALTHY VOLUNTEERS

1998 ◽  
Vol 89 (Supplement) ◽  
pp. 1333A
Author(s):  
Thomas Frietsch ◽  
Heiko Fessler ◽  
Arnulf Lorentz ◽  
Michael Kirschfink ◽  
Klaus F. Waschke
Keyword(s):  
Immune System ◽  
Healthy Volunteers ◽  
Whole Blood ◽  
Fresh Frozen Plasma ◽  
Red Cells ◽  
Autologous Whole Blood ◽  
Fresh Frozen ◽  
Frozen Plasma

Fresh frozen plasma: red blood cells (1:2) coagulation effect is equivalent to 1:1 and whole blood

2015 ◽  
Vol 199 (2) ◽  
pp. 608-614 ◽  
Author(s):  
Joao B. Rezende-Neto ◽  
Gilberto P. Rodrigues ◽  
Thiago A. Lisboa ◽  
Mario Carvalho-Junior ◽  
Maria Julia Silva ◽  
...  
Keyword(s):  
Red Blood Cells ◽  
Whole Blood ◽  
Blood Cells ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Frozen Plasma
Sign in / Sign up

Export Citation Format

Share Document